Yes, negatives and not as we hoped, but a) we didn't pay for it,...

Yes, negatives and not as we hoped, but a) we didn't pay for it, and b) there are positive outcomes. Investigators want to do a second run, and it is possible it will also be paid for by someone else, again. Investigators probably like what they see.

If the trial required patients to have had no prior anti biotics, then that was never going to fly, hence low recruitment. There is obviously enough evidence to now say, lets do this treatment as a first course of treatment vs current standard of care.

People shouldn't lose sight of that.

The upcoming CR has already been cornerstoned as mentioned by the Company, and I will take up anything they throw at me.